Åmic, Uppsala SE-751 83, Sweden.
Anal Biochem. 2011 Feb 1;409(1):7-13. doi: 10.1016/j.ab.2010.09.034. Epub 2010 Sep 26.
Several new plasma protein biomarkers have been associated with increased risk of cardiovascular events. It would be of great value if sets of these markers could be measured in a multiplexed format at point-of-care settings. A major challenge is the extremely wide concentration range in which different plasma biomarkers are present. Two promising biomarkers for cardiac risk prediction are C-reactive protein (CRP) and N-terminal pro-brain natriuretic peptide (NTproBNP). The concentrations of these markers can differ by more than six orders of magnitude. Here we present a chip-based multiplexed assay for CRP and NTproBNP. The high-concentration analyte, CRP, is analyzed in a competitive format, whereas the low-concentration analyte, NTproBNP, is analyzed in a sandwich format. This allows concurrent measurement of the two analytes in a single multiplexed assay. The dynamic ranges for the two assays were optimized to match the relevant serum concentration ranges; thus, no dilutions were needed. Both assays exhibit good precision (5-15% in the clinically relevant concentration ranges), and the limit of detection for the NTproBNP assay was 5 ng/L. Patient plasma samples were used for comparison with clinical methods, resulting in coefficients of determination (R(2)) of 0.9762 and 0.9606 for NTproBNP and CRP, respectively.
已有一些新的血浆蛋白生物标志物与心血管事件风险增加相关。如果能在床边检测点以多重检测的方式检测这些标志物就好了。一个主要的挑战是不同的血浆生物标志物存在着极其广泛的浓度范围。两个有前途的用于心脏风险预测的生物标志物是 C 反应蛋白(CRP)和 N 末端脑利钠肽前体(NTproBNP)。这些标志物的浓度可以相差 6 个数量级以上。在这里,我们提出了一种基于芯片的 CRP 和 NTproBNP 的多重检测方法。高浓度分析物 CRP 采用竞争格式进行分析,而低浓度分析物 NTproBNP 采用夹心格式进行分析。这使得两种分析物可以在单个多重检测中同时进行测量。两个分析的动态范围都经过优化以匹配相关的血清浓度范围,因此无需稀释。两种分析的精密度都很好(在临床相关的浓度范围内为 5-15%),NTproBNP 分析的检测限为 5ng/L。使用患者的血浆样本与临床方法进行比较,得到 NTproBNP 和 CRP 的决定系数(R(2))分别为 0.9762 和 0.9606。